NCT06525649View on ClinicalTrials.gov

A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 21, 2024

Primary Completion Date

June 26, 2025

Study Completion Date

June 26, 2025

Conditions
Photosensitive EpilepsyEpilepsy
Interventions
DRUG

NPT 2042

NPT 2042 is a new drug being developed as an anti-seizure treatment.

Trial Locations (2)

77205

Clinical Trials, Inc. (CTI), Little Rock

83702

Idaho Comprehensive Epilepsy Center, Boise

Sponsors
All Listed Sponsors
collaborator

The Epilepsy Study Consortium

OTHER

lead

NeuroPro Therapeutics, Inc.

INDUSTRY

NCT06525649 - A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042 | Biotech Hunter | Biotech Hunter